st.diallo

TL2 Moderator · Cork

Contributes reviews on supplier material. Based in Cork.

Joined 22 September 2025 · last posted 15d

72Posts here

1Topics

2Solutions

572Likes received

288Likes given

20Badges

161Days visited

2kPosts read

Recent activity

Full stream

[2026 update] Travelling with an injectable: documentation and practicalities Replied, post #77 · Access › International · 13 Jul 2026 · 15 likes post #76 is right about the mechanism and I think understates the practical bit. For anyone arriving from a search: the marked solution above is the direct answer, and…
Prior authorisation: what the criteria usually require — a second dataset Replied, post #14 · Access › Insurance & coverage · 10 Jul 2026 · 23 likes post #13 answers the question as asked. The question underneath it is different. Documentation your clinician can provide: letters from clinicians describing why…
What is genuinely unknown about long-term amylin agonism Replied, post #8 · Compounds › Cagrilintide & amylin analogues · 6 Jul 2026 · 5 likes Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own…
Leak-back after withdrawal and whether you lost a meaningful dose Started this topic · Practice › Administration · 5 Jul 2026 · 0 likes Posting this under the heading it deserves: Leak-back after withdrawal and whether you lost a meaningful dose Everything below is what sits behind that. Reporting…
Interim analyses and stopping rules Replied, post #28 · Evidence › Trials · 26 Jun 2026 · 4 likes Picking up post #25: that is the part I would want checked first. Open-label design: unblinded trials admit expectation effects. For weight-loss trials where one arm…
Personal or family history of medullary thyroid carcinoma Replied, post #5 · Safety › Contraindications · 22 Jun 2026 · 25 likes Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing. The correction was fair and I had…
Review: a draft on reconstitution arithmetic, with objections — one year on Replied, post #27 · Documentation › Doc review · 13 Jun 2026 · 28 likes Review of promoted topics: when a topic is nominated for promotion to a maintained documentation page, the draft is posted here. Community review happens before…
Primary endpoint hierarchies and why order matters — one year on Replied, post #12 · Evidence › Trials · 11 Jun 2026 · 5 likes The estimand: what the trial set out to estimate. Two trials can be identical in structure but estimate different things by using different handling rules for people…
[2026 update] A vial that will not fully dissolve: what to check and in what order Replied, post #93 · Practice › Reconstitution · 6 Jun 2026 · 1 like On post #89 — agreed on the reasoning, with one qualification. How much of the diluent volume the powder itself displaces: for a small peptide vial, the powder volume…
Comparing prices across jurisdictions without misleading yourself Replied, post #38 · Access › Pricing · 4 Jun 2026 · 24 likes Coming back to post #36, because the follow-up matters more than the original answer. Subscription services and subscriptions: some online clinics bundle compounds into…
Molecular mass of semaglutide and why the figure differs between sources Replied, post #65 · Compounds › Semaglutide · 27 May 2026 · 14 likes Semaglutide versus liraglutide in STEP 8: semaglutide produced greater weight reduction and the discontinuation rates differed. But the trial was open-label for the…
How Janoshik, Medutest, PeptideMeter and VendorInvestigate differ — does this still hold? Replied, post #18 · Sourcing › Independent verification · 25 May 2026 · 0 likes Medutest: combined purity and identity reporting. Appears throughout vendor documentation. Where a submission has been blind we note it because blind results are worth…